ERBB2 and neoplasm: At an E/T ratio of 10/1 (Fig. 3c), 20 % targeted killing of KATO III (left panel) and 50 % killing of SKBR-3 (right panel) tumor cells was still obtained with 1 μg/ml (13 nM) of HER2 and/or CEA-targeted CD1d fusion proteins, demonstrating the sensitivity of this approach.